Vigil Neuro
Matthew Figley is a Principal Scientist at Vigil Neuroscience, where Matthew discovers and develops novel therapeutics based on breakthroughs in basic science and human genetics of microglia. Prior to this role, Matthew was a Postdoctoral Research Scholar at Washington University in St. Louis, focusing on the molecular mechanisms of Wallerian axon degeneration. Matthew completed their Ph.D. in Neuroscience at Stanford University, where Matthew studied the genetics of Amyotrophic Lateral Sclerosis (ALS) in Aaron Gitler's lab. Matthew holds a Bachelor of Science degree in Neuroscience & History and Philosophy of Science from the University of Pittsburgh.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.